Intravenous immunoglobulin (IVIG) is a blood/plasma product, which is prepared from the serum of multiple of donors, used to treat patients with antibody deficiency. The isolated plasma product is clinically treated and purified to Ig, which further facilitates the treatment. IVIG is applicable in various fields such as hematology, immunology, neurology, dermatology, nephrology, ophthalmology, and rheumatology.
The Malaysia IVIG market was valued at $12,277 thousand in 2015, and is projected to reach $18,649 thousand by 2022, registering a CAGR of 6.1% during the forecast period. This is attributed to increase in prevalence of chronic inflammatory demyelinating polyneuropathy (CIDP) & hypogammaglobulinemia and rise in use of immunoglobulins to treat Guillain-Barre syndrome (GBS), inflammatory myopathies, specific antibody deficiency, and others. Increase in geriatric population & number of hemophilic patients, improved IVIG production owing to the emergence of advanced technologies, and enhanced purification techniques (with better plasma yield) drive the growth of the market. However, stringent government regulations toward IVIG products, expensive therapy, and high risk of side effects associated with the use of IVIG are expected to hamper the market growth.
The report segments the Malaysia IVIG market based on application, product type, mode of delivery, and concentration by both- value and volume. Applications covered in the study include hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, GBS, Kawasaki disease, secondary immune deficiency disease, and others.
Hypogammaglobulinemia and CIDP held dominant market shares in 2015 due to the large patient population and unavailability of effective alternatives to IVIG treatment. Based on product type, the market is segmented into immunoglobulin G (IgG), IgA, IgM, IgE, and IgD. By mode of delivery, it is bifurcated into intravenous, subcutaneous, and intramuscular. On the basis of concentration, it is categorized into 5%, 10%, and others. The intravenous mode of delivery segment held the largest revenue share in 2015, and is anticipated to continue this trend during the forecast period.
KEY PLAYERS PROFILED
KEY MARKET BENEFITS FOR STAKEHOLDERS
KEY MARKET SEGMENTS
By Mode of Delivery
The other players in the value chain include (profiles not included in the report)
The Global Cloud Gaming market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) of XX% from between 2016 and 2022. This report studies the global Cloud Gaming market, especially in North America, Europe, Asia-Pacific, South America, Middle ...
November 2017 | $4960 |View Details>>
In 2016, the Asia-Pacific Cloud Gaming market size was xx million USD and it will reach xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. This report studies Cloud Gaming in Asia-Pacific market, especially in China, Japan, Korea, Taiwan, India, Australia, Indonesia, Thailand and Philippines, focuses ...
November 2017 | $4660 |View Details>>
In 2016, the Cloud Gaming market size was xx million USD in China, and it will be xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. In China market, the top players include Sony GameFly (PlayCast) Nvidia ...
November 2017 | $3360 |View Details>>
In 2016, the Europe Cloud Gaming market size was xx million USD and it will reach xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. This report studies Cloud Gaming in Europe market, especially in Germany, UK, France, Italy, Russia, Benelux, Turkey and other countries in ...
November 2017 | $4660 |View Details>>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research